Page 166 - 南京医科大学自然版

第45卷第6期
·904 · 南 京 医 科 大 学 学 报 2025年6月

［9］ HAYFLICK S J，WESTAWAY S K，LEVINSON B，et al. and genotype ⁃ phenotype correlation of pantothenate ki⁃
Genetic，clinical，and radiographic delineation of Haller⁃ nase ⁃ associated neurodegeneration［J］. CNS Neurosci
vorden⁃Spatz syndrome［J］. N Engl J Med，2003，348（1）： Ther，2020，26（7）：754-761
33-40 ［19］中华医学会神经病学分会帕金森病及运动障碍学组，
［10］AGOSTINI F，SGALLETTA B，BISAGLIA M. Iron dysho⁃ 中国医师协会神经内科医师分会帕金森病及运动障碍
meostasis in neurodegeneration with brain iron accumula⁃ 专业. 脑组织铁沉积神经变性病诊治专家共识［J］. 中
tion（NBIA）：is it the cause or the effect?［J］. Cells，2024， 华医学杂志，2016，96（27）：2126-2133
13（16）：1376 Parkinson’s Disease and Movement Disorders Group，Chi⁃
［11］CHIAPPARINI L，SAVOIARDO M，D’ARRIGO S，et al. nese Society of Neurology，Chinese Medical Association，
The“eye⁃of⁃the⁃tiger”sign may be absent in the early Parkinson’s Disease and Movement Disorders Specialty
stages of classic pantothenate kinase associated neurode⁃ Group，Chinese Neurologists Association of Chinese Medi⁃
generation［J］. Neuropediatrics，2011，42（4）：159-162 cal Doctor Association. Expert consensus on the diagnosis
［12］BAUMEISTER F A，AUER D P，HÖRTNAGEL K，et al. and treatment of neurodegenerative diseases with brain
The eye⁃of⁃the⁃tiger sign is not a reliable disease marker iron accumulation［J］. National Medical Journal of China，
for Hallervorden ⁃ Spatz syndrome［J］. Neuropediatrics， 2016，96（27）：2126-2133

2005，36（3）：221-222 ［20］HOGARTH P，KURIAN M A，GREGORY A，et al. Con⁃
［13］HAYFLICK S J，HARTMAN M，CORYELL J，et al. Brain sensus clinical management guideline for pantothenate ki⁃
MRI in neurodegeneration with brain iron accumulation nase⁃associated neurodegeneration（PKAN）［J］. Mol Gen⁃
with and without PANK2 mutations［J］. AJNR Am J Neu⁃ et Metab，2017，120（3）：278-287
roradiol，2006，27（6）：1230-1233 ［21］KLOPSTOCK T，VIDENOVIC A，BISCHOFF A T，et al.
［14］DELGADO R F，SANCHEZ P R，SPECKTER H，et al. Fosmetpantotenate randomized controlled trial in panto⁃
Missense PANK2 mutation without “eye of the tiger” thenate kinase⁃associated neurodegeneration［J］. Mov Dis⁃
sign：MR findings in a large group of patients with panto⁃ ord，2021，36（6）：1342-1352
thenate kinase⁃associated neurodegeneration（PKAN）［J］. ［22］KLOPSTOCK T，TRICTA F，NEUMAYR L，et al. Safety
J Magn Reson Imaging，2012，35（4）：788-794 and efficacy of deferiprone for pantothenate kinase⁃associ⁃
［15］VALENTINO P，ANNESI G，CIRÒ CANDIANO I C，et al. ated neurodegeneration：a randomised，double⁃blind，con⁃
Genetic heterogeneity in patients with pantothenate kinase trolled trial and an open⁃label extension study［J］. Lancet
⁃associated neurodegeneration and classic magnetic reso⁃ Neurol，2019，18（7）：631-642
nance imaging eye⁃of⁃the⁃tiger pattern［J］. Mov Disord， ［23］SVETEL M，TOMIC A，DRAGAŠEVIC N，et al. Clinical
2006，21（2）：252-254 course of patients with pantothenate kinase ⁃ associated
［16］BARRITT S A，DUBOIS⁃COYNE S E，DIBBLE C C. Co⁃ neurodegeneration（PKAN）before and after DBS sur⁃
enzyme a biosynthesis：mechanisms of regulation，func⁃ gery［J］. J Neurol，2019，266（12）：2962-2969
tion and disease［J］. Nat Metab，2024，6（6）：1008-1023 ［24］POHANE M R，DAFRE R，SONTAKKE N G. Diagnosis
［17］LI W B，SHEN N X，ZHANG C，et al. Novel PANK2 mu⁃ and treatment of pantothenate kinase⁃associated neurode⁃
tations in patients with pantothenate kinase ⁃ associated generation（PKAN）：a systematic review［J］. Cureus，
neurodegeneration and the genotype⁃phenotype correla⁃ 2023，15（9）：e46135
tion［J］. Front Aging Neurosci，2022，14：848919 ［收稿日期］ 2024-10-30
［18］CHANG X，ZHANG J，JIANG Y，et al. Natural history （本文编辑：唐 震）